

BIOPATCH® Protective Disk with CHG Fact Checker



BIOPATCH® Disk



AEGIS™ CHG Disk


Indicated to reduce catheter related bloodstream infections (CRBSI) in patients with central venous or arterial catheters?	Yes ¹	No
Randomized controlled trials demonstrating CRBSI reduction?	15+ ²⁻⁴	0
Meets the CDC 1A recommendation for prevention of intravascular catheter related infections?	Yes ⁵	No
Multiple meta-analyses evaluating CRBSIs?	Yes	No
Trusted by more than 70% of hospitals across the nation?	Yes ⁶	No ⁶
Over 25 years of extensive clinical use?	Yes ⁷	No
Anti-infective dressing contract position with major GPOs?	Yes	No
CHG continuously released over 7 days to maintain skin antiseptics?	Yes ⁸	No

Microbiologic Test Results⁹

Methods:⁹ Using zone of inhibition (ZOI) assay, each test article and its corresponding negative control were evaluated for their antimicrobial efficacy against the below 7 challenge microbes on Mueller Hinton agar.

Conclusion:⁹ AEGIS™ showed activity against gram positive bacteria and yeast; however, AEGIS™ efficacy against gram negative bacteria was variable. The AEGIS™ dressing exhibited limited efficacy against *Paeruginosa* and *A. baumannii*. It is important to note that the efficacy against these two challenge organisms was static and the organisms present in the zone area were not killed, and were able to grow back when cultured. The AEGIS™ dressing failed the swab test for all other challenge organisms as well from day six.

Days With Sustained Microbial Activity Under The Dressings - 7 Challenge Organisms



Infection Risk
Management

Proven. Preferred. Designed to Deliver.



ORDER CODE	4150	4151	4152
Size	1" disc (2.5cm) w/4.0mm center hole	3/4" disc (1.9cm) w/1.5mm center hole	1" disc (2.5cm) w/7.0mm center hole
FRENCH SIZE RANGE	6-12Fr	<6Fr	13-20Fr
Common Uses	Central Lines PICC	Peripheral IVs Huber Needles (ports) Arterial Lines Extended Dwell PIVs Midlines PICCs Pins	Dialysis Catheters Drains Sheaths Cordis Catheters VAD drive lines
QUANTITY PER CASE	10/box 4 boxes/case, 40	10/box 4 boxes/case, 40	10/box 4 boxes/case, 40
AVERAGE CHG PER DISK	92 mg	52.5 mg	86.8 mg

Please visit biopatch.com for Full Prescribing Information.

The third-party trademark used herein is the trademark of the respective owner.

References: **1.** BIOPATCH® Protective Disk with CHG, Instructions for Use, Ethicon Inc. 2012 **2.** BIOPATCH clinical compendium, 077880-170803 **3.** Levy, I. et al. Chlorhexidine-Impregnated Dressing for Prevention of Colonization of Central Venous Catheters in Infants and Children. The Pediatric Infectious Disease Journal. 2005 August;24: 676-679 **4.** Garland, J. et al. A Randomized Trial Comparing Povidone-Iodine to a Chlorhexidine Gluconate-Impregnated Dressing for Prevention of Central Venous Catheter Infections in Neonates. Pediatrics. 2001;107:1431 **5.** 2017 Updated Recommendations on the Use of Chlorhexidine-Impregnated Dressings for Prevention of Intravascular Catheter-Related Infections Published Nov 1, 2017 **6.** Global Business Insights June 2018 Market Share Report **7.** Biopatch Original 510K submission: Prepared by VitaPhore Corporation. Premarket Notification, 510(k) : Regulatory Requirements for Medical Devices. Rockville, Md. : Washington, D.C. :U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Devices and Radiological Health ; For sale by the Supt. of Docs, U.S. G.P.O., 1989. Print. **8.** Bhende MS, Rothenburger S. In vitro antimicrobial effectiveness of 5 catheter insertion-site dressings. The Journal of the Association for Vascular Access. 2007; 12(4):227-231 **9.** Bhende S. Study report for in vitro microbiological evaluation of Antimicrobial Barrier Dressings using zone of inhibition assay. Ethicon notebook. 2016; 4487:70-77.

Infection Risk Management

ETHICON
PART OF THE **Johnson & Johnson** FAMILY OF COMPANIES

© 2018 Ethicon US, LLC. All Rights Reserved. 102943-181120